Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
Symtuza protease inhibitor regimen maintains viral suppression for a year

People who switched from a multi-pill antiretroviral regimen to the first one-pill, once-daily regimen that includes a protease inhibitor maintained undetectable viral load for a year, according to

Published
13 October 2017
By
Liz Highleyman
Long-acting monoclonal antibody effective against multidrug-resistant HIV

Ibalizumab, a long-acting monoclonal antibody that prevents HIV from entering cells, maintained viral suppression for a year in people with highly resistant HIV and limited

Published
12 October 2017
By
Liz Highleyman
Antibody-Based HIV Tx Proves Durable

The monoclonal antibody HIV drug ibalizumab, designed for patients who've developed severe drug resistance, had long-lasting protection in the 24-week extension phase of a phase III trial, researchers reported here.

Published
10 October 2017
From
MedPage Today
Bictegravir-Containing Regimen Found to Be Non-Inferior to Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adult Patients with HIV

Gilead Sciences, Inc. (NASDAQ: GILD) today announced detailed 48-week results from a Phase 3 study (Study 1878) evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone.

Published
04 October 2017
From
Gilead press release
The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir

The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under review in the United States and the European Union as part of a once-daily, single-tablet HIV regimen. The licence allows manufacturers to develop and sell generic medicines containing BIC, if approved in the United States, in 116 low- and middle-income countries where more than 30 million people live with HIV.

Published
04 October 2017
From
Medicines Patent Pool
Promising HIV Treatments in Late-Stage Clinical Development

The following monotherapies and combination regimens are in late-stage clinical development or FDA review.

Published
02 October 2017
From
P&T Community
Single-pill HIV treatment to save SA R11bn – health ministry

A single-pill HIV treatment is expected to be introduced in 2018 and is projected to save SA about R11bn over the following six years, the health ministry announced on Friday.

Published
25 September 2017
From
News24
New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low-and middle-income countries at reduced price

A breakthrough pricing agreement has been announced which will accelerate the availability of the first affordable, generic, single-pill HIV treatment regimen containing dolutegravir (DTG) to public sector purchasers in low- and middle-income countries (LMICs) at around US$75 per person, per year.

Published
22 September 2017
From
UNAIDS
Immune 'Cocktails' Likely Needed in HIV

Immunological attack on HIV, whether for prevention or treatment, is likely to have important similarities to current drug therapies, two research papers suggest.

Published
21 September 2017
From
MedPage Today HIV/AIDS
Maraviroc matches boosted protease inhibitor treatment over 96 weeks

Treatment with maraviroc (Celsentri/Selzentry) is associated with durable HIV suppression and a favourable lipid profile, investigators report in HIV Medicine. The 96-week randomised study compared

Published
11 September 2017
By
Michael Carter
← First12345...98Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.